Genflow Biosciences PLC Secures Grant Funding

Genflow Biosciences Plc, a pioneering company in the field of longevity research, has announced that it has received a significant portion of a research grant from the Government of Wallonia in Belgium. The grant, which totals €381,434, will fund the company's sarcopenia research project and is part of Belgium's Advanced Therapy Medicinal Products (ATMPs) initiative. This funding is non-dilutive and non-reimbursable, providing a solid financial foundation for Genflow's innovative work without affecting shareholder equity or requiring repayment.

Genflow Biosciences, in collaboration with its partner Revatis SA, has embarked on a three-year research initiative aimed at combating sarcopenia, a condition characterized by age-related loss of muscle mass and function. Sarcopenia is a significant health issue that primarily affects older adults, leading to reduced mobility and increased risk of falls and fractures. The research project focuses on developing muscle progenitor cells (MPCs) enhanced with Genflow's proprietary SIRT6 gene to promote muscle regeneration and address the root causes of sarcopenia.

Muscle progenitor cells are a type of stem cell with the ability to transform into muscle cells, playing a crucial role in repairing and regenerating muscle tissue. In individuals suffering from sarcopenia, the quantity and activity of these cells decline, impairing muscle regeneration. By incorporating the SIRT6 gene into MPCs, Genflow aims to boost the cells' regenerative capacity, thereby mitigating the adverse effects of aging on muscle tissues. The ultimate goal of this research is to develop therapeutic solutions that can significantly improve the quality of life for individuals affected by muscle loss and weakness due to aging.

Dr. Eric Leire, CEO of Genflow, emphasized the importance of this research, stating that sarcopenia is a major health issue worldwide. "Our Sarcopenia program aims to counteract the detrimental effects of aging on muscle tissue, holding potential for significantly improving the quality of life for older adults affected by muscle loss and weakness," Dr. Leire said.

The funding will be used as working capital to support the Sarcopenia project over the next two years. The remaining funds from the grant will be disbursed based on submitted invoices, ensuring that the project has the financial resources needed to progress.

Genflow Biosciences, founded in 2020, is dedicated to developing gene therapies that slow down the aging process, with the broader objective of promoting longer and healthier lives. The company's lead compound, GF-1002, involves the delivery of a centenarian variant of the SIRT6 gene, which has shown promising results in preclinical studies. Genflow plans to begin clinical trials in 2025 to explore the potential benefits of GF-1002 in treating Metabolic Dysfunction-Associated Steatohepatitis (MASH), a common chronic liver disease currently lacking effective treatments.

The company's headquarters are in the UK, with research and development facilities in Belgium. Genflow is listed on the London Stock Exchange (LSE:GENF) and on the OTCQB market (OTCQB:GENFF). The company's mission is to develop innovative therapies that not only extend lifespan but also improve the quality of life, addressing the financial, emotional, and social impacts of an aging global population.

In conclusion, the receipt of this grant marks a significant milestone for Genflow Biosciences in its quest to pioneer effective treatments for age-related diseases like sarcopenia. Through its cutting-edge research and strategic partnerships, Genflow continues to lead the way in the field of longevity science, promising a future where aging and its associated diseases can be more effectively managed.